Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when HAE files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsHaemonetics elects Carlyle healthcare exec to board, shareholders approve equity plan expansion
Filed July 28, 2026 · Period ending July 24, 2026 · ~1 min read
Key Changes
-
medium
Martin Madaus, Senior Operating Executive at The Carlyle Group with 30+ years in diagnostics and life sciences, elected to board effective July 24, 2026. Previously led turnarounds at Ortho Clinical Diagnostics and Millipore Corporation.
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation verify on EDGAR → -
medium
Shareholders approved 4,680,000 additional shares for the Long-Term Incentive Plan and extended the plan through 2036 (94.8% of votes cast, 83.0% of shares outstanding).
Item 5.07 — Submission of Matters to a Vote of Security Holders verify on EDGAR → -
low
All eight directors elected with 97.4%–99.7% support; say-on-pay approved with 98.6% support; Ernst & Young ratified as auditor with 98.3% support.
Item 5.07 — Submission of Matters to a Vote of Security Holders verify on EDGAR → -
low
Madaus to serve on Audit and Governance committees; will receive standard non-employee director compensation including ~$200,000 annual equity award.
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation verify on EDGAR →
Summary
Haemonetics added Martin Madaus to its board effective July 24, 2026, bringing healthcare investment and operational expertise from The Carlyle Group, where he has advised on healthcare investments since 2019. Dr. Madaus previously led business turnarounds at Ortho Clinical Diagnostics (following its Johnson & Johnson carve-out) and Millipore Corporation (culminating in its 2010 acquisition by Merck KGaA).
He currently chairs Repligen Corporation's board and serves on Azenta's board. At the July 24 annual meeting, shareholders approved amendments to the company's equity compensation plans. The Long-Term Incentive Plan amendment authorizes 4,680,000 additional shares and extends the plan through 2036, passing with 94.8% of votes cast (83.0% of shares outstanding).
The Employee Stock Purchase Plan was extended through 2036 with 99.9% approval. All governance proposals passed with routine support levels: director elections received 97.4%–99.7% approval, say-on-pay received 98.6% approval, and auditor ratification received 98.3% approval. The equity plan expansion provides additional capacity for employee and executive compensation through the next decade.
Section-by-Section Diff
Event · Exhibit 99.1
Added in current filing · view on EDGAR →
Previously, Dr. Madaus served as Chairman and Chief Executive Officer of Ortho Clinical Diagnostics, Inc. (now QuidelOrtho Corporation), a global provider of in vitro diagnostics, where he led the company’s business turnaround following its carve-out from Johnson & Johnson.
Dr. Madaus previously led Ortho Clinical Diagnostics as Chairman and CEO, where he executed a business turnaround after the company was carved out from Johnson & Johnson. This experience in transforming a separated business unit may be relevant to Haemonetics' strategic initiatives.
Added in current filing · view on EDGAR →
Earlier, as Chairman, President and Chief Executive Officer of Millipore Corporation, he led the company's transformation into a leading life sciences company, culminating in its acquisition by Merck KGaA in 2010.
Dr. Madaus led Millipore Corporation's transformation into a leading life sciences company as Chairman, President and CEO, which resulted in its acquisition by Merck KGaA in 2010. This track record of value creation through operational transformation and strategic transactions adds relevant expertise to Haemonetics' board.
Show 1 minor / wording change
Added in current filing · view on EDGAR →
Dr. Madaus is an active board leader and currently serves as Chair of the Board of Repligen Corporation and as a member of the board of directors of Azenta, Inc.
Dr. Madaus currently serves as Chair of Repligen Corporation's board and as a director of Azenta, Inc., demonstrating active board leadership in the life sciences sector. His concurrent board roles provide additional industry perspective and governance experience.
Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On July 24, 2026, the Board of Directors of Haemonetics Corporation (the “Company”) elected Martin Madaus as a director of the Company, effective immediately. Dr. Madaus currently serves as Senior Operating Executive at The Carlyle Group, where since 2019 he has advised on healthcare investments and portfolio company performance.
Haemonetics added Martin Madaus to its Board of Directors. Dr. Madaus brings healthcare investment and operational expertise from his role at The Carlyle Group, where he has advised on healthcare investments and portfolio company performance since 2019. He will stand for shareholder election at the 2027 annual meeting.
Show 2 minor / wording changes
Added in current filing · verify on EDGAR →
Dr. Madaus, who will stand for election by shareholders at the Company’s 2027 annual meeting of shareholders, is expected to be appointed to serve on the Audit Committee and the Governance and Compliance Committee of the Board of Directors.
Dr. Madaus is expected to serve on both the Audit Committee and the Governance and Compliance Committee. These committee assignments indicate he will have oversight roles in financial reporting and corporate governance matters.
Added in current filing · verify on EDGAR →
As a non-employee director of the Company, Dr. Madaus will receive compensation as described in the “Directors’ Compensation” section of the Company’s definitive proxy statement for the 2026 annual meeting of shareholders, with an annual equity award having an approximate value of $200,000.
Dr. Madaus will receive standard non-employee director compensation, including an annual equity award valued at approximately $200,000. This aligns with the company's existing director compensation structure disclosed in the 2026 proxy statement.
Event · Item 5.07 — Submission of Matters to a Vote of Security Holders
Haemonetics shareholders approved equity plan amendments, director elections, say-on-pay, and auditor ratification at the July 24, 2026 annual meeting.
Added in current filing · verify on EDGAR →
on July 24, 2026, the shareholders of the Company approved an amendment and restatement of the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan (the “Amended Plan”), which authorizes 4,680,000 additional shares for issuance under the Amended Plan, extends the term of the Amended Plan through 2036 and makes certain other technical, immaterial and conforming changes.
Shareholders approved an amendment to the 2019 Long-Term Incentive Compensation Plan that authorizes 4,680,000 additional shares for equity awards and extends the plan's term through 2036. The vote was 37,730,923 for, 2,055,726 against, and 48,989 abstentions, representing 94.8% approval of votes cast and 83.0% of shares outstanding.
Show 4 minor / wording changes
Added in current filing · verify on EDGAR →
on July 24, 2026, the shareholders of the Company also approved an amendment and restatement of the Haemonetics Corporation Amended and Restated 2007 Employee Stock Purchase Plan (as amended, the “ESPP”), which extends the term of the ESPP through 2036 and makes certain other technical, immaterial and conforming changes.
Shareholders approved an amendment to the 2007 Employee Stock Purchase Plan extending its term through 2036. The vote was 39,766,894 for, 27,909 against, and 40,835 abstentions, representing 99.9% approval of votes cast and 87.5% of shares outstanding.
Added in current filing · view on EDGAR →
Christopher A. Simon 39,671,163 164,476 2,215,467
Robert E. Abernathy 39,223,620 612,019 2,215,467
Diane M. Bryant 39,702,050 133,589 2,215,467
Michael J. Coyle 39,633,794 201,845 2,215,467
Lloyd E. Johnson 39,241,021 594,618 2,215,467
Mark W. Kroll 39,232,256 603,383 2,215,467
Claire Pomeroy 39,624,390 211,249 2,215,467
Ellen M. Zane 38,813,643 1,021,996 2,215,467
All eight director nominees were elected for one-year terms expiring in 2027. Support ranged from 97.4% to 99.7% of votes cast and 85.4% to 87.4% of shares outstanding, reflecting routine approval levels for uncontested director elections.
Added in current filing · verify on EDGAR →
Of the 45,445,983 shares outstanding and entitled to vote at the meeting, 42,051,106 shares were represented at the meeting, constituting a quorum of 92.53%. ... 39,212,253 572,620 50,766 2,215,467
Shareholders approved executive compensation on an advisory basis with 39,212,253 votes for, 572,620 against, and 50,766 abstentions. This represents 98.6% approval of votes cast and 86.3% of shares outstanding, a routine approval level indicating strong shareholder support for the compensation program.
Added in current filing · verify on EDGAR →
The shareholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending April 3, 2027 based upon the following votes:
For Against Abstain
41,321,226 716,413 13,467
Shareholders ratified Ernst & Young LLP as the independent auditor for fiscal year 2027 with 41,321,226 votes for, 716,413 against, and 13,467 abstentions, representing 98.3% approval of votes cast and 90.9% of shares outstanding.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jul 29, 2026 · How we verify